Tezepelumab-Ekko (Tezspire), tezepelumab-ekko
Named-patient access overview. Tezepelumab-Ekko (Tezspire) is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Tezepelumab Ekko
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Tezepelumab-Ekko (Tezspire)
Tezepelumab-Ekko (Tezspire) (tezepelumab-ekko) is manufactured by Amgen / AstraZeneca and indicated for Severe asthma add-on maintenance (any phenotype). It is an anti-TSLP monoclonal antibody (subcutaneous) approved by the US FDA in 2021 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Tezepelumab-Ekko (Tezspire)
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Tezepelumab-Ekko (Tezspire) for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Tezepelumab-Ekko (Tezspire) is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. If you are pursuing Tezepelumab-Ekko (Tezspire) for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Tezepelumab-Ekko (Tezspire) is in our coordination scope. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Tezepelumab-Ekko (Tezspire)
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.